Key Market Indicator:
F&G: 63
26.107,75 NASDAQ · 49.098,00 DOW · 6.991,20 S&P · 5.514,04 Gold · 68,66 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
CH0038389992
Filter zurücksetzen
© EQS Newswire
23.01.2026
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Vorläufige Jahresergebnisse 2025 und Dividendenvorschlag
Article
News Preview
Medienmitteilung vom 23. Januar 2026BB Biotech: Vorläufige Jahresergebnisse 2025 und Dividendenvorschlag BB Biotech AG gibt für 2025 die folgenden vorläufigen und ungeprüften Finanzergebnisse bekannt: Gesamtjahr 2025: Die Aktie von BB Biotech erzielte eine starke Gesamtrendite von +34.2% in CHF, +37.0% in EUR und +53.7% in USD (inklusive der im M......
Themefolio
Profiler
Peergroup
© EQS Newswire
28.10.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Edison issues report on BB Biotech (BION)
Article
News Preview
  London, UK, 28 October 2025   Edison issues report on BB Biotech (BION) Edison issues report on BB Biotech (SIX: BION) BB Biotech (BION) delivered strong Q325 results, underpinned by its focus on innovative biotech companies with differentiated clinical pipelines and promising long-term potential. NAV increased 24.0% (in CHF terms) and its s......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.10.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech AG veröffentlicht Zwischenbericht
Article
News Preview
Ad hoc-Mitteilung gemäss Art. 53 KR 24. Oktober 2025BB Biotech AG veröffentlicht Zwischenbericht Die BB Biotech AG (ISIN CH0038389992) hat heute den Zwischenbericht per 30. September 2025 veröffentlicht, welcher über die Ergebnisentwicklung für die ersten neun Monate 2025 informiert. Basierend auf den konsolidierten Zahlen weist die BB Biotech A......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© EQS Newswire
24.10.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech AG publishes its interim report
Article
News Preview
Ad hoc announcement pursuant to Art. 53 LR October 24, 2025 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2025, which covers the results of its business activities for the first nine months of 2025. Based on the consolidated accounts of BB Biotech AG, net prof......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© EQS Newswire
24.10.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Portfolio outperformance amid early signs of sector recovery
Article
News Preview
Media release as at October 24, 2025 BB Biotech Q3 2025: Portfolio outperformance amid early signs of sector recovery Share price: +20.0% in CHF / +20.1% in EUR / +19.5% in USD – notably outperforming the Nasdaq Biotech Index (NBI), which gained +15.6% in USD  NAV: +24.0% in CHF / +24.0% in EUR / +23.5% in USD – surpassing the benchmark NBI by 7......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.10.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Portfolio übertrifft Benchmark – erste Anzeichen einer Branchen-Erholung
Article
News Preview
Medienmitteilung vom 24. Oktober 2025 BB Biotech Q3 2025: Portfolio übertrifft Benchmark – erste Anzeichen einer Branchen-Erholung Aktienkurs: +20.0% in CHF / +20.1% in EUR / +19.5% in USD – deutlich besser als der Nasdaq Biotech Index (NBI), der um +15.6% in USD zulegte  NAV: +24.0% in CHF / +24.0% in EUR / +23.5% in USD – eine Outperformance v......
Themefolio
Profiler
Peergroup
© EQS Newswire
22.09.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech wird in den SPI ESG Index aufgenommen
Article
News Preview
Medienmitteilung vom 22. September 2025 BB Biotech wird in den SPI ESG Index aufgenommen Die BB Biotech AG gibt bekannt, dass sie per heute, 22. September 2025 in den SPI ESG Index der SIX Swiss Exchange aufgenommen wird. Damit wird das langjährige Engagement der Investmentgesellschaft für verantwortungsbewusstes Investieren und nachhaltige Unter......
Themefolio
Profiler
Peergroup
© EQS Newswire
22.09.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech to be included in the SPI ESG Index
Article
News Preview
Media release as at September 22, 2025 BB Biotech to be included in the SPI ESG Index BB Biotech AG announces that it will be included in the SPI ESG Index of the SIX Swiss Exchange as of today, September 22, 2025. This highlights the investment company’s long-standing commitment to responsible investing and sustainable corporate governance. Dr.......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.07.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech AG publishes its interim report
Article
News Preview
Ad hoc announcement pursuant to Art. 53 LR July 25, 2025 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2025, which covers the results of its business activities for the first six months of 2025. Based on the consolidated accounts of BB Biotech AG, net loss for the ......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.07.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech AG veröffentlicht Zwischenbericht
Article
News Preview
Ad hoc-Mitteilung gemäss Art. 53 KR 25. Juli 2025 BB Biotech AG veröffentlicht Zwischenbericht Die BB Biotech AG (ISIN CH0038389992) hat heute den Zwischenbericht per 30. Juni 2025 veröffentlicht, welcher über die Ergebnisentwicklung für das 1. Halbjahr 2025 informiert. Basierend auf den konsolidierten Zahlen weist die BB Biotech AG im Zwischen......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.07.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Outperformance zum Nasdaq Biotech Index – Starke Entwicklung in USD, Wechselkurs belastet Ergebnis in CHF
Article
News Preview
Medienmitteilung vom 25. Juli 2025 BB Biotech Q2 2025: Outperformance zum Nasdaq Biotech Index – Starke Entwicklung in USD, Wechselkurs belastet Ergebnis in CHF Aktienkurs legt in USD um 10.2% zu; in CHF -1.1%, in EUR +0.8% – Abschlag zum NAV sinkt auf 10.5% NAV entwickelt sich in USD um 5.8% positiv; in CHF -5.1%, in EUR -2.8% – damit 5.9 Proze......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.07.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
outperforms Nasdaq Biotech Index; strong USD returns, currency drag in CHF
Article
News Preview
Media release as at July 25, 2025 BB Biotech Q2 2025: outperforms Nasdaq Biotech Index; strong USD returns, currency drag in CHF Share price +10.2 % USD / -1.1% CHF / +0.8% EUR; discount to NAV tightens to 10.5% NAV +5.8% USD / -5.1% CHF / -2.8% EUR; beating NBI by 5.9 percentage points Net loss of CHF 100 mn in Q2; FX the main drag (USD vs CHF......
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
10.06.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Edison issues report on BB Biotech (BION)
Article
News Preview
  London, UK, 10 June 2025   Edison issues report on BB Biotech (BION) Edison issues report on BB Biotech (BION). During 2024 and early this year, the biotech sector began to show signs of a structural recovery, supported by positive clinical data, regulatory approvals, lower interest rates, commercial execution and Johnson & Johnson’s acq......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.04.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech AG publishes its interim report
Article
News Preview
Ad hoc announcement pursuant to Art. 53 LR April 25, 2025 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2025, which covers the results of its business activities for the first three months of 2025. Based on the consolidated accounts of BB Biotech AG, net loss for ......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.04.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech AG veröffentlicht Zwischenbericht
Article
News Preview
Ad hoc-Mitteilung gemäss Art. 53 KR 25. April 2025 BB Biotech AG veröffentlicht Zwischenbericht Die BB Biotech AG (ISIN CH0038389992) hat heute den Zwischenbericht per 31. März 2025 veröffentlicht, welcher über die Ergebnisentwicklung für die ersten drei Monate 2025 informiert. Basierend auf den konsolidierten Zahlen weist die BB Biotech AG im ......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.04.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Sharpened portfolio focus amid continued market volatility
Article
News Preview
Media release as at April 25, 2025 BB Biotech Q1 2025: Sharpened portfolio focus amid continued market volatility The first quarter of 2025 was marked by elevated market volatility and rising macro uncertainty, driven by geopolitical developments and trade tensions. Biotech valuations, especially in small- and mid-cap names, remained under pressu......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.04.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Portfoliofokus inmitten anhaltender Volatilität geschärft
Article
News Preview
Medienmitteilung vom 25. April 2025 BB Biotech im Q1 2025: Portfoliofokus inmitten anhaltender Volatilität geschärft Das 1. Quartal 2025 war geprägt von erhöhter Marktvolatilität und zunehmender makroökonomischer Unsicherheit, ausgelöst durch geopolitische Entwicklungen und handelspolitische Spannungen. Die Bewertungen im Biotechnologiesektor – i......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.03.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu und genehmigt die Dividende von CHF 1.80 pro Aktie
Article
News Preview
Medienmitteilung vom 19. März 2025 Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu und genehmigt die Dividende von CHF 1.80 pro Aktie An der ordentlichen Generalversammlung der BB Biotech AG von heute haben die Aktionäre sämtliche Anträge des Verwaltungsrats angenommen. Die Aktionäre stimmten einer Dividendenausschüttung von CH......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.03.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share
Article
News Preview
Media release of March 19, 2025 Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 1.80 per share All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech AG's shareholders at its Annual General Meeting held today. Shareholders voted in favor of the proposal to pay out a divi......
Themefolio
Profiler
Peergroup
© EQS Newswire
21.02.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech AG publishes its 2024 annual report
Article
News Preview
Ad hoc announcement pursuant to Art. 53 LR February 21, 2025 Annual report of BB Biotech AG as at December 31, 2024  BB Biotech AG publishes its 2024 annual report BB Biotech AG published its annual report for fiscal year 2024 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the bi......
Themefolio
Profiler
Peergroup
© EQS Newswire
21.02.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech AG veröffentlicht Geschäftsbericht 2024
Article
News Preview
Ad hoc-Mitteilung gemäss Art. 53 KR 21. Februar 2025 Geschäftsbericht der BB Biotech AG per 31. Dezember 2024 BB Biotech AG veröffentlicht Geschäftsbericht 2024 Die BB Biotech AG hat heute ihren Geschäftsbericht für das Jahr 2024 veröffentlicht. Der Bericht enthält neben den geprüften Jahresabschlusszahlen auch ausführliche Informationen zum Bi......
Themefolio
Profiler
Peergroup
© EQS Newswire
21.02.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech positions for structural sector recovery amid shifting market dynamics
Article
News Preview
Media release as at February 21, 2025 Annual Report 2024: BB Biotech positions for structural sector recovery amid shifting market dynamics 2024, especially the fourth quarter, signaled the early stage of a structural recovery in biotech, driven by renewed investor focus on clinical data, regulatory approvals, and commercial execution. BB Biotec......
Themefolio
Profiler
Peergroup
© EQS Newswire
21.02.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech positioniert sich in einem herausfordernden Markt mit ersten Erholungstendenzen
Article
News Preview
Medienmitteilung vom 21. Februar 2025 Geschäftsbericht 2024: BB Biotech positioniert sich in einem herausfordernden Markt mit ersten Erholungstendenzen Im 4. Quartal setzte eine strukturelle Erholung im Biotechsektor ein, getrieben durch das wiedererstarkte Anlegerinteresse an klinischen Daten, Zulassungen und erfolgreicher Kommerzialisierung. 2......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.01.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Preliminary full-year 2024 results and dividend proposal
Article
News Preview
Media release as of January 24, 2025 BB Biotech: Preliminary full-year 2024 results and dividend proposal BB Biotech AG reports the following preliminary and unaudited figures for 2024: Full-year 2024: BB Biotech shares delivered a total return of -13.5% in CHF and -14.1% in EUR (including the CHF 2.00 dividend paid in March 2024). NAV performan......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.01.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Vorläufige Jahresergebnisse 2024 und Dividendenvorschlag
Article
News Preview
Medienmitteilung vom 24. Januar 2025 BB Biotech: Vorläufige Jahresergebnisse 2024 und Dividendenvorschlag  Die BB Biotech AG gibt für 2024 die folgenden vorläufigen und ungeprüften Finanzergebnisse bekannt: Gesamtjahr 2024: Die Aktie von BB Biotech erzielte eine negative Gesamtrendite von 13.5% in CHF und 14.1% in EUR (einschliesslich der im März......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.01.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech AG closes the 2024 fiscal year with a profit
Article
News Preview
Ad hoc announcement pursuant to Art. 53 LR January 24, 2025 BB Biotech AG closes the 2024 fiscal year with a profit In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information: Based on its preliminary unaudited consolidated figures, BB Biotech AG reports a profit of approximately......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.01.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech AG mit Gewinn im Geschäftsjahr 2024
Article
News Preview
Ad hoc-Mitteilung gemäss Art. 53 KR 24. Januar 2025 BB Biotech AG mit Gewinn im Geschäftsjahr 2024 Die BB Biotech AG (ISIN CH0038389992) informiert im Einklang mit der Ad-hoc-Publizitätspflicht über folgendes: Basierend auf den noch nicht geprüften konsolidierten Zahlen weist die BB Biotech AG für das Geschäftsjahr 2024 einen Gewinn von rund CH......
Themefolio
Profiler
Peergroup
© EQS Newswire
22.01.2025
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Edison issues report on BB Biotech (BION)
Article
News Preview
  London, UK, 22 January 2025   Edison issues report on BB Biotech (BION) Edison issues report on BB Biotech (BION). BB Biotech (BION) is the largest biotech investor among its investment company peers. The company is focused on achieving long-term capital growth by investing in high-quality biotech assets developing and marketing innovative d......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.10.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech AG publishes its interim report
Article
News Preview
Ad hoc announcement pursuant to Art. 53 LR October 25, 2024 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2024, which covers the results of its business activities for the first nine months of 2024. Based on the consolidated accounts of BB Biotech AG, net prof......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.10.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech AG veröffentlicht Zwischenbericht
Article
News Preview
Ad hoc-Mitteilung gemäss Art. 53 KR 25. Oktober 2024 BB Biotech AG veröffentlicht Zwischenbericht Die BB Biotech AG (ISIN CH0038389992) hat heute den Zwischenbericht per 30. September 2024 veröffentlicht, welcher über die Ergebnisentwicklung für die ersten neun Monate 2024 informiert. Basierend auf den konsolidierten Zahlen weist die BB Biotech......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.10.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Strategic reallocation of portfolio assets progressing
Article
News Preview
Media release as at October 25, 2024 Portfolio of BB Biotech AG as at September 30, 2024 BB Biotech: Strategic reallocation of portfolio assets progressing In the third quarter of 2024, stock markets remained volatile. The recent rate cut by the US central bank has improved the market dynamics for the biotechnology sector because lower interest ......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.10.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Strategische Reallokationen im Portfolio setzen sich fort
Article
News Preview
Medienmitteilung vom 25. Oktober 2024 Zwischenbericht der BB Biotech AG per 30. September 2024 BB Biotech: Strategische Reallokationen im Portfolio setzen sich fort Die Aktienmärkte blieben auch im 3. Quartal volatil. Die Zinssenkung der US-Notenbank verbessert die Ausgangslage für den Biotechsektor, da tiefere Zinsen grundsätzlich Kapital in Wac......
Themefolio
Profiler
Peergroup
© EQS Newswire
23.10.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Edison issues report on BB Biotech (BION)
Article
News Preview
  London, UK, 23 October 2024   Edison issues report on BB Biotech (BION) Edison issues report on BB Biotech (BION). BB Biotech (BION) invests in innovative, rapidly expanding biotech companies. BION’s portfolio company Wave Life Sciences (Wave) recently announced a significant milestone in the field of genetic medicine: the first successful t......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.07.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech AG veröffentlicht Zwischenbericht und kündigt Führungswechsel im Investment Management Team an
Article
News Preview
Ad hoc-Mitteilung gemäss Art. 53 KR 26. Juli 2024 BB Biotech AG veröffentlicht Zwischenbericht und kündigt Führungswechsel im Investment Management Team an Die BB Biotech AG (ISIN CH0038389992) hat heute den Zwischenbericht per 30. Juni 2024 veröffentlicht, welcher über die Ergebnisentwicklung für das 1. Halbjahr 2024 informiert. Basierend auf ......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.07.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech AG publishes its interim report and announces a new head of its investment management team
Article
News Preview
Ad hoc announcement pursuant to Art. 53 LR July 26, 2024 BB Biotech AG publishes its interim report and announces a new head of its investment management team BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2024, which covers the results of its business activities for the first six months of 2024. Based on th......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.07.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Substanzielle Fortschritte einiger Portfoliounternehmen federn zinsbedingte Marktvolatilität ab
Article
News Preview
Medienmitteilung vom 26. Juli 2024 Portfolio der BB Biotech AG per 30. Juni 2024 Substanzielle Fortschritte einiger Portfoliounternehmen federn zinsbedingte Marktvolatilität ab Während die Aktienmärkte, angeführt von einigen grossen Technologieunternehmen, neue Höchststände erreichten, blieb der Gesundheitssektor im 2. Quartal in der Gunst der A......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.07.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Substantial pipeline progress at several portfolio companies offsets rate-related market volatility
Article
News Preview
Media release as at July 26, 2024 Portfolio of BB Biotech AG as at June 30, 2024 Substantial pipeline progress at several portfolio companies offsets rate-related market volatility Global equity indices climbed to new record highs during the second quarter, driven by just a few mega tech stocks, but investors continued to shun the healthcare sec......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.06.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Edison issues report on BB Biotech (BION)
Article
News Preview
  London, UK, 26 Juni 2024   Edison issues report on BB Biotech (BION) Click here to view the full report. All reports published by Edison are available to download free of charge from its website www.edisongroup.com Edison is authorised and regulated by the Financial Conduct Authority. Edison is not an adviser or broker-dealer and does not......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.05.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
A recovering sector with a healthy prognosis
Article
News Preview
  London, UK, 20 May 2024   Edison issues review on BB Biotech (BION): A recovering sector with a healthy prognosis BB Biotech (BION) offers investors exposure to the innovative, rapidly expanding biotech sector. It is the largest biotech investor among its investment company peers, focused on high-quality biotech assets that target substantial......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.04.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech AG publishes its interim report
Article
News Preview
Ad hoc announcement pursuant to Art. 53 LR April 26, 2024 BB Biotech AG publishes its interim report BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2024, which covers the results of its business activities for the first three months of 2024. Based on the consolidated accounts of BB Biotech AG, net profit fo......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.04.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech AG veröffentlicht Zwischenbericht
Article
News Preview
Ad hoc-Mitteilung gemäss Art. 53 KR 26. April 2024 BB Biotech AG veröffentlicht Zwischenbericht Die BB Biotech AG (ISIN CH0038389992) hat heute den Zwischenbericht per 31. März 2024 veröffentlicht, welcher über die Ergebnisentwicklung für die ersten drei Monate 2024 informiert. Basierend auf den konsolidierten Zahlen weist die BB Biotech AG im ......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.04.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
Article
News Preview
Media release as at April 26, 2024 Portfolio of BB Biotech AG as at March 31, 2024 BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates Investor sentiment in the biotech space continues to be shaped by the general interest rate environment. Biotechnology stocks traded higher early in ......
Themefolio
Profiler
Peergroup
© EQS Newswire
26.04.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech mit solidem Quartalsergebnis, Biotechkapitalmarkt von Zinserwartungen geprägt
Article
News Preview
Medienmitteilung vom 26. April 2024 Portfolio der BB Biotech AG per 31. März 2024 BB Biotech mit solidem Quartalsergebnis, Biotechkapitalmarkt von Zinserwartungen geprägt Das Zinsumfeld bestimmt weiterhin massgeblich die Stimmung der Biotechinvestoren. Die Aktienkurse entwickelten sich zu Beginn des Jahres vielversprechend, erhielten dann aber e......
Themefolio
Profiler
Peergroup
© EQS Newswire
21.03.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu und genehmigt die Dividende von CHF 2.00 pro Aktie
Article
News Preview
Medienmitteilung vom 21. März 2024 Die Generalversammlung der BB Biotech AG stimmt allen Anträgen zu und genehmigt die Dividende von CHF 2.00 pro Aktie An der ordentlichen Generalversammlung der BB Biotech AG von heute haben die Aktionäre sämtliche Anträge des Verwaltungsrats angenommen. Die Aktionäre stimmten einer Dividendenausschüttung von CH......
Themefolio
Profiler
Peergroup
© EQS Newswire
21.03.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share
Article
News Preview
Media release of March 21, 2024 Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.00 per share All proposals of BB Biotech AG's Board of Directors were approved by BB Biotech AG's shareholders at its Annual General Meeting held today. Shareholders voted in favor of the proposal to pay out a divi......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.02.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech AG veröffentlicht Geschäftsbericht 2023
Article
News Preview
Ad hoc-Mitteilung gemäss Art. 53 KR 16. Februar 2024 Geschäftsbericht der BB Biotech AG per 31. Dezember 2023 BB Biotech AG veröffentlicht Geschäftsbericht 2023 Die BB Biotech AG hat heute ihren Geschäftsbericht für das Jahr 2023 vorgelegt. Der Bericht enthält neben den geprüften Jahresabschlusszahlen auch ausführliche Informationen zum Biotech......
Themefolio
Profiler
Peergroup
© EQS Newswire
16.02.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech AG publishes its 2023 annual report
Article
News Preview
Ad hoc announcement pursuant to Art. 53 LR February 16, 2024 Annual report of BB Biotech AG as at December 31, 2023  BB Biotech AG publishes its 2023 annual report BB Biotech AG published its annual report for fiscal year 2023 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the bi......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.02.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Anlegerinteresse kehrt zurück – Unverändert hohe Dividendenrendite im 2024
Article
News Preview
Mitteilung vom 14. Februar 2024Anlegerinteresse kehrt zurück – Unverändert hohe Dividendenrendite im 2024 Nach einem schwierigen Börsenjahr 2023, dessen Hauptursache die steigenden Zinsen waren, haben die Kapitalmärkte inzwischen wieder Gefallen an Biotechunternehmen gefunden. Die Aussicht auf sinkende Zinsen hat zu einem Umdenken geführt. Während......
Themefolio
Profiler
Peergroup
© EQS Newswire
14.02.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Investor interest returns – dividend yield remains high for 2024
Article
News Preview
Release as at February 14, 2024Investor interest returns – dividend yield remains high for 2024 After a difficult 2023 stock market year, above all due to higher interest rates, the capital markets are now once again looking at biotech companies with interest. The prospect of falling interest rates has led to a rethink. While the majority of inves......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.01.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech AG publiziert Geschäftsergebnis 2023 und gibt Veränderungen im Verwaltungsrat bekannt
Article
News Preview
Ad hoc-Mitteilung gemäss Art. 53 KR 19. Januar 2024 BB Biotech AG publiziert Geschäftsergebnis 2023 und gibt Veränderungen im Verwaltungsrat bekannt Die BB Biotech AG (ISIN CH0038389992) informiert im Einklang mit der Ad-hoc-Publizitätspflicht über folgendes: Geschäftsergebnis 2023 Basierend auf den noch nicht geprüften konsolidierten Zahlen we......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.01.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors
Article
News Preview
Ad hoc announcement pursuant to Art. 53 LR January 19, 2024 BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information: Results for the financial year 2023 Based on its preliminary unaudited ......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.01.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
Jahresendrally des Biotechsektors durch M&A-Aktivitäten und Zinswende beflügelt
Article
News Preview
Medienmitteilung vom 19. Januar 2024 Portfolio der BB Biotech AG per 31. Dezember 2023 Jahresendrally des Biotechsektors durch M&A-Aktivitäten und Zinswende beflügelt Die globalen Aktienmärkte entwickelten sich 2023 besser als von vielen Marktteilnehmern erwartet. Die US-Notenbank verlangsamte Anfang 2023 das Tempo ihrer Zinserhöhungen und s......
Themefolio
Profiler
Peergroup
© EQS Newswire
19.01.2024
ISIN: CH0038389992
BB Biotech AG
BION
LISTED
SIX
End of year biotech equity market rally – M&A and end of rate hike cycle
Article
News Preview
Media release as at January 19, 2024 Portfolio of BB Biotech AG as at December 31, 2023 End of year biotech equity market rally – M&A and end of rate hike cycle In 2023, global equity performed better than anticipated by many. The US central bank moderated and then paused interest rate hikes. These developments resulted in a year-end bond ma......
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2026 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Thursday, 29.01.2026, Calendar Week 05, 29th day of the year, 336 days remaining until EoY.